Apollomics Announces Private Placement Financing and Addition to Board of Directors
Apollomics Inc. - Class A Ordinary Shares (APLM)
Company Research
Source: GlobeNewswire
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it entered into subscription agreements for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses. The PIPE financing included participation from both new and existing investors. Pursuant to the terms of the subscription agreements, Apollomics is selling an aggregate of 19,166,666 Class A ordinary shares at a price of $0.30 per share. The PIPE financing is expected to close on May 8, 2024, subject to satisfaction of customary closing conditions. Apollomics intends to use the net proceeds from the PIPE financing, together with the Apollomics’ existing cash, cash equivalents, and marketable securities, to
Show less
Read more
Impact Snapshot
Event Time:
APLM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APLM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APLM alerts
High impacting Apollomics Inc. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
APLM
News
- Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Apollomics Announces Presentation at the 2024 BIO International ConventionGlobeNewswire
- Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $5.00 to $2.00. They now have a "buy" rating on the stock.MarketBeat
- Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneGlobeNewswire
APLM
Sec Filings
- 5/30/24 - Form SC
- 5/30/24 - Form EFFECT
- 5/29/24 - Form 424B3
- APLM's page on the SEC website